PEP-Therapy, a Paris, France-based biotechnology company, raised an additional €2.6m ($3m) in an extension of its Series A financing round.
The funding, which brought the total raised in the round to date to €5.4m ($6.4m) included €1.6m in equity from Anaxago, i&i Prague and BADGE as well as a €1m loan from Bpifrance.
The company intends to use the funds to finance the Phase I a/b clinical trial of PEP-010, its lead candidate, for the treatment of advanced solid tumors.
Led by CEO Antoine Prestant, PEP-Therapy is a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers. PEP-010 is the first of a new class of therapeutic peptides based on its innovative Cell Penetrating & Interfering Peptide (CP&IP) technology. These molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms, without altering physiological mechanisms.
PEP-Therapy and its clinical partners, Institut Curie and Gustave Roussy, previously received a €2.9m grant from the French state innovation fund – Fonds Unique Interministériel (FUI) – to finance nonclinical and early clinical development of PEP-010.
FinSMEs
19/07/2021